Analyst Insights

Canaccord Raises Price Target On Medifast; Expects Improved Profitability

In a research note released today, Canaccord analyst Scott Van Winkle maintained his Hold position on Medifast (MED) and upgraded his price target to $32.00 from $31.

OraSure Technologies Price Target Raised at Canaccord Following Agreement With AbbVie

In a research note issued today, Canaccord analyst Mark Massaro reiterated a Buy rating and boosted his price target on OraSure Technologies (OSUR) to $11.00 …

Valeant Pharmaceuticals Reiterated With A Buy At Canaccord

In a research note issued today, Canaccord maintained coverage with a “Buy” rating on Valeant Pharmaceuticals (VRX), and a price target of $168.00 a share.

Canaccord Downgrades B/E Aerospace to Hold As Company Sale Looks Incrementally Less Likely

In a research report issued today, B/E Aerospace Inc. (BEAV) was downgraded by analyst Kenneth Herbert at Canaccord from a “buy” rating to a “hold” rating.

Wedbush Reiterates Outperform On Itron; Expects An Incrementally Positive Long-Term Outlook

In a research note released today, Wedbush reiterated coverage on Itron (ITRI) with an Outperform rating and a price target of $41. Wedbush analyst Craig Irwin believes that business …

Roth Capital Sees Downside in Dendreon Corporation Shares

In a research note issued today, Roth Capital reiterated coverage with a “Sell” rating on Dendreon Corporation (DNDN) and lowered its price target to $0.50 from …

Maxim Group Assumes Advanced Cell Technology at Buy

In a research note released today, Maxim Group assumed coverage on Advanced Cell Technology, Inc. (ACTC) with a Buy rating and a price …

Roth Capital Reaffirms EnteroMedics at Buy; Positive Bias Heading Into The FDA Panel

In a research note issued today, Roth Capital reiterated coverage with a “Buy” rating on EnteroMedics Inc. (ETRM), and a price target of $3.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts